CRISPR-Cas9 gave researchers a comparatively cheap, precise way to edit DNA, and with that capability came a specific, technical fault line that the entire CRISPR ethics debate actually runs along: whether an edit is somatic (made in the body cells of an existing person, affecting only that individual) or germline (made in eggs, sperm, or an early embryo, and therefore heritable — passed on to every descendant of that person). Almost every disagreement in this field, from what’s legal to what a research ethics committee will approve, traces back to that distinction.
Somatic vs. germline editing — why the distinction is the whole debate
Somatic gene editing changes cells in a living person’s body — blood stem cells, liver cells, retinal cells — without touching reproductive cells. The edit dies with the patient; it is never passed to their children. This is now an approved category of medicine: in December 2023 the US FDA approved the first CRISPR-based therapy, a somatic-cell treatment for sickle cell disease and transfusion-dependent beta thalassemia, developed by Vertex Pharmaceuticals and CRISPR Therapeutics. It is regulated the same way any other gene therapy or biologic is — through the standard drug-approval pathway, with IRB review of the clinical trials that supported it and ordinary informed consent from adult participants.
Germline gene editing is categorically different, because the person whose genome is permanently altered — the resulting child, and every one of their descendants — cannot consent to the edit before it happens. That single fact is why germline editing is treated as ethically distinct from every other form of medical intervention, and why, as of 2026, no country has approved it for clinical reproductive use. Somatic editing raises the ordinary ethical questions of any experimental therapy (safety, informed consent, equitable access); germline editing raises those plus questions about consent across generations, unintended effects on the human gene pool, and the risk of edits used for enhancement rather than disease prevention.
The 2018 He Jiankui case
In November 2018, Chinese researcher He Jiankui announced, on the eve of the Second International Summit on Human Genome Editing in Hong Kong, that he had created the first gene-edited human babies: twin girls, referred to publicly as “Lulu” and “Nana,” born from embryos he had edited with CRISPR-Cas9 to disable the CCR5 gene, intending to confer resistance to HIV. A third child from a separate pregnancy in his study was born the following year and confirmed only later.
A Chinese court investigation subsequently found that He and two collaborators, Zhang Renli and Qin Jinzhou, had forged ethical review documents and misled the physicians and participants involved about the true nature of the procedure. In December 2019, the Shenzhen Nanshan District People’s Court sentenced He Jiankui to three years in prison and a fine of 3 million yuan (approximately $430,000), for the crime of “illegal medical practice” — at the time, Chinese criminal law had no offense specific to unauthorized human germline editing, so prosecutors used the closest available charge. Zhang and Qin received shorter sentences and smaller fines. He was released from prison in April 2022, and by late 2022 had opened a new lab and stated publicly that his future work would focus on gene therapies for rare diseases rather than heritable embryo editing.
The case became the reference point for the entire field not because germline editing itself was new as a concept, but because it demonstrated, concretely, what happens when someone moves ahead without genuine ethical oversight: forged consent documentation, no peer-reviewed preclinical safety case, and human subjects — both the mothers and the resulting children — who could not meaningfully consent to risks that had never been through the kind of independent review a IRB or REC is supposed to provide.
International reaction and moratorium calls
The reaction was immediate and came from the scientific community itself, not only from regulators. The Second International Summit’s organizing committee issued a statement the same week calling He’s work “irresponsible,” citing inadequate medical justification, procedural failures in the ethical review, and a lack of transparency in how the research was conducted and disclosed.
In March 2019, a group of prominent scientists and ethicists — including Eric Lander, Françoise Baylis, Feng Zhang, and Emmanuelle Charpentier (a co-developer of CRISPR-Cas9 as a gene-editing tool) — published a comment in Nature calling for a global moratorium on clinical germline editing until a broad international framework for evaluating its safety, efficacy, and permissible uses is in place. It stopped short of calling for a permanent ban, framing the moratorium as a pause pending governance, not a rejection of the technology in principle.
The World Health Organization convened an Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing in 2019, in direct response to the He Jiankui case. In 2021 the committee published recommendations calling on WHO to strengthen governance of the field, including maintaining a public registry of human genome-editing research (the WHO Registry, launched in 2019), and it did not endorse clinical use of heritable editing.
Separately, an International Commission on the Clinical Use of Human Germline Genome Editing — convened by the US National Academy of Medicine, the US National Academy of Sciences, and the UK’s Royal Society — published a report in September 2020 concluding that heritable genome editing is not ready for clinical use, while outlining the scientific and ethical criteria that would need to be met before any country considered permitting a narrow initial clinical application. A Third International Summit on Human Genome Editing was held in London in March 2023, continuing the same standing forum.
Regulatory frameworks — how oversight actually works today
No single global law bans germline human genome editing; oversight is a patchwork of national law, funding restrictions, and professional self-governance:
- United States. Congress has attached a rider to the FDA’s annual appropriations act every year since the version signed in December 2015 (covering fiscal year 2016 onward) that bars the FDA from using any of its funds to review or approve an application for clinical use of a drug or biological product “in which a human embryo is intentionally created or modified to include a heritable genetic modification.” The effect is not a direct criminal ban on germline editing research itself, but a closed regulatory pathway: there is currently no legal route to bring a heritable human genome edit into a US clinical trial, because the FDA is barred from even reviewing the application.
- China. At the time of the He Jiankui case, Chinese criminal law had no offense specific to unauthorized embryo gene editing, which is why prosecutors relied on “illegal medical practice.” The 11th Amendment to China’s Criminal Law, enacted in December 2020 and effective March 1, 2021, closed that gap: it created a specific criminal offense for implanting a gene-edited or cloned human embryo into a human or animal (or a gene-edited/cloned animal embryo into a human), carrying a sentence of three to seven years’ imprisonment plus fines — making heritable human genome editing for reproductive purposes explicitly criminal in China for the first time.
- Most other jurisdictions that regulate human embryo research at all — including much of Europe under the Oviedo Convention’s prohibition on germline intervention, and countries with dedicated embryo-research statutes — already prohibited or did not permit heritable clinical genome editing before 2018; the He Jiankui case reinforced rather than originated most of these positions.
- Somatic gene editing, by contrast, is regulated as an ordinary category of biomedical research and therapy in essentially every jurisdiction with a functioning research-oversight system: standard IRB/REC review under frameworks like the US Common Rule, plus the normal drug- and biologic-approval process. See CASRAI’s guide to the IRB/REC approval process for how that review actually works.
Why this belongs in a research ethics office’s scope
Very few institutions will ever propose heritable germline editing — the regulatory and funding pathways described above effectively foreclose it. But the underlying ethical framework the He Jiankui case exposed as having failed is the same framework that governs every other human-subjects protocol a research ethics office reviews. The Belmont Report‘s three core principles map directly onto what went wrong in that case: respect for persons (the forged consent documents meant the participants could not exercise genuine autonomy), beneficence (the risk-benefit calculus for editing a healthy embryo to prevent a risk — HIV transmission — that already had established, lower-risk prevention methods was never independently assessed), and justice (questions about who would have access to genome-editing technology, and whether it would be used for treatment or enhancement, went unaddressed).
For research administrators, the practical relevance is in the adjacent, active categories: somatic CRISPR gene-therapy trials go through ordinary IRB review like any other clinical protocol; any embryo-related or reproductive-cell research proposal warrants particular scrutiny against institutional policy and national law before it reaches a funding or ethics decision; and the broader CRISPR ethics debate is a live, recurring example institutions use in informed consent and responsible-conduct-of-research training precisely because it is real, documented, and legally resolved — not hypothetical.
Frequently asked questions
Is CRISPR gene editing on humans legal?
It depends entirely on the type. Somatic (non-heritable) CRISPR therapies are legal and, in some cases, FDA-approved, when they go through the normal clinical-trial and drug-approval process. Germline (heritable) editing of human embryos for reproductive purposes is not legally available anywhere as an approved clinical procedure; in the US, an appropriations rider blocks the FDA from even reviewing such an application, and in China it is now a specific criminal offense.
What is the difference between somatic and germline gene editing?
Somatic editing changes cells in an existing person’s body and is not passed to their children. Germline editing changes eggs, sperm, or an early embryo, making the change heritable — passed to all of that person’s descendants. This is the central ethical and regulatory dividing line in the entire field.
What happened to He Jiankui?
He Jiankui announced in November 2018 that he had used CRISPR-Cas9 to edit the embryos that became twin girls born that year, plus a third child born in 2019, without adequate ethical review or genuine informed consent. A Chinese court found that he and two collaborators had forged ethics-approval documents, and in December 2019 sentenced him to three years in prison and a 3-million-yuan fine for illegal medical practice. He was released in April 2022.
Has any country banned germline gene editing?
China’s 11th Amendment to its Criminal Law (effective March 2021) makes implanting a gene-edited human embryo a specific criminal offense. The US does not have an outright criminal ban, but an annual FDA appropriations rider has, since fiscal year 2016, blocked any legal path for a heritable-genome-editing application to reach clinical trials. Many other countries prohibit heritable human embryo modification under existing embryo-research or bioethics law.
Did the scientific community call for a moratorium on CRISPR?
In March 2019, a group of scientists and ethicists published a call in Nature for a global moratorium on clinical germline editing, pending an international governance framework — not a permanent ban. The World Health Organization and a joint US National Academies/Royal Society commission separately concluded, in 2020 and 2021, that heritable editing was not ready for clinical use and required stronger international oversight.
Related CASRAI Dictionary terms
Belmont Report · Informed consent · IRB (Institutional Review Board) · REC (Research Ethics Committee) · Common Rule (45 CFR 46) · Research misconduct
